Table 1

Characteristics of the study population at baselinea

Total Sample (n = 127)

Contingency Management (n = 70)

Control (n = 57)


Recruitment

Peer-referral

64 (50)

35 (50)

29 (51)

Healthcare provider, STD or HIV clinic

28 (22)

15 (21)

13 (24)

Self-referral via community advertising

21 (16)

13 (19)

8 (14)

Community-based organization

7 (5)

4 (6)

3 (5)

Other, unknown

7 (5)

3 (4)

4 (7)

Randomization

1:1

100 (79)

50 (71)

50 (88)

3:1

27 (21)

20 (29)

7 (12)

Demographics

Age (years, median [range])

39 (18-60)

40 (18-60)

37 (19-57)

Race/Ethnicityb

Black, African American

10 (8)

2 (3)

8 (14)

Hispanic, Latino

17 (13)

12 (17)

5 (9)

Native American, Alaska Native

8 (6)

4 (6)

4 (7)

White

76 (60)

47 (67)

29 (51)

Other race/ethnicity, multiracial, unknown

16 (13)

5 (7)

11 (19)

Education

Less than High School

19 (15)

10 (14)

9 (16)

High School

30 (24)

17 (24)

13 (23)

Some college, vocational/technical training

60 (47)

35 (50)

25 (45)

College or greater

13 (10)

6 (9)

7 (12)

Missing

5 (4)

2 (3)

2 (4)

Annual income less than $15,000

90 (71)

53 (76)

37 (65)

Homeless or marginally housed

27 (21)

17 (24)

10 (17)

Neither employed nor attending school

89 (70)

51 (73)

38 (67)

HIV status

Negative

57 (45)

30 (43)

27 (47)

Positive

70 (55)

40 (57)

30 (53)

Sexual orientation

Gay, homosexual

80 (63)

47 (67)

33 (58)

Bisexual

28 (22)

14 (20)

14 (25)

Straight, heterosexual

1 (1)

1 (1)

0

Queer, same gender loving, other

18 (14)

8 (11)

10 (17)

Sexual Behavior, prior 6 weeks

Number of sex partners (median [IQR])

3 (2-8)

4 (2-10)

3 (2-6.5)

Number of anal sex partners (median [IQR])

2 (1-5)

2 (1-6)

2 (1-5)

Number of nonconcordant UAI partners (median [range])

0 (0-35)

0 (0-35)

0 (0-16)

Nonconcordant UAI

35 (28)

21 (30)

14 (25)

Use of methamphetamine with anal sex

102 (80)

59 (84)

43 (75)

Exchanged sex for methamphetamine

20 (16)

11 (16)

9 (16)

Methamphetamine Use

Duration of methamphetamine use, years (median [IQR])

11 (5-19)

14 (6-19)

11 (5-16)

Weekly or daily methamphetamine use, prior 6 weeks

83 (65)

51 (73)

32 (56)

Used more than 8 quarters of methamphetamine, prior 6 weeks

59 (46)

37 (53)

22 (39)

Injection of methamphetamine, prior 6 weeks

69 (54)

41 (59)

28 (49)

Trans-theoretical stage of change: "Have you been trying to stop or cut down on your methamphetamine use?"

"Yes, I have been trying for more than 6 months" (Maintenance)

49 (39)

25 (36)

24 (42)

"Yes, I have been trying for less than 6 months"

(Action)

24 (19)

12 (17)

12 (21)

"No, but I really want to start this month" (Preparation)

14 (11)

11 (16)

3 (5)

"No, but I really would like to try in the next 6 months" (Contemplation)

14 (11)

9 (13)

5 (9)

"No, and I am really not interested in trying" (Pre-contemplation)

6 (5)

3 (4)

3 (5)

Missing

20 (16)

10 (14)

10 (17)

Ever been in substance abuse treatment for methamphetamine use

32 (25)

17 (24)

15 (26)

Ever attended a support group for methamphetamine use

52 (41)

25 (36)

27 (47)

Other substance use, prior 6 weeks

Cocaine

35 (28)

17 (24)

18 (32)

Crack

53 (42)

26 (37)

27 (47)

Inhaled nitrites

59 (46)

35 (50)

24 (42)

Erectile dysfunction medications

39 (31)

26 (37)

13 (23)

Ecstasy

19 (15)

8 (11)

11 (19)

Gamma-hydroxybutyrate

25 (20)

16 (23)

9 (16)

Urine testing results

Urine positive for methamphetamine

44 (35)

28 (40)

16 (28)

Urine positive for cocaine metabolites

31 (24)

12 (17)

19 (33)

Urine positive for methamphetamine or cocaine metabolites

65 (51)

35 (50)

30 (53)


IQR, interquartile range; UAI, unprotected anal intercourse.

aData are n (%) unless otherwise noted.

b P < 0.05

Menza et al. BMC Public Health 2010 10:774   doi:10.1186/1471-2458-10-774

Open Data